Drugs / mRNA-1273.617.2
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05289037 | Mar 2022 → Nov 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04927065 | May 2021 → Nov 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1273.617.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04927065 ↗ |
| Modality | Messenger RNA (mRNA) | “containing an mRNA that encodes for the prefusion stabilized S protein” NCT05289037 ↗ |
| Route | Intramuscular | “Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.617.2 on Day 1.” NCT04927065 ↗ |